NPI: 1699743930 · WESTON, FL 33331 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/11/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/11/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 178 | $54K |
| 2019 | 8,115 | $1.35M |
| 2020 | 9,934 | $1.53M |
| 2021 | 463 | $81K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 7,202 | 254 | $1.12M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 6,944 | 352 | $1.10M |
| J1270 | Injection, doxercalciferol, 1 mcg | 2,700 | 160 | $448K |
| A4657 | Syringe, with or without needle, each | 542 | 278 | $160K |
| 85048 | 375 | 238 | $55K | |
| 85041 | 375 | 238 | $55K | |
| 82728 | 120 | 80 | $19K | |
| 83970 | 106 | 66 | $19K | |
| 83540 | 99 | 66 | $14K | |
| 83550 | 93 | 62 | $14K | |
| J1756 | Injection, iron sucrose, 1 mg | 78 | 12 | $5K |
| 82108 | 34 | 24 | $4K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 22 | 13 | $0.00 |